{"id":"539f4dcd-e408-42f4-8686-12db9fe5c78e","question":"How does renal impairment affect the plasma concentrations and LDL-C reduction of LIPITOR?","reference_answer":"Renal impairment has no influence on the plasma concentrations or LDL-C reduction of LIPITOR.","reference_context":"Document 91: Excretion\nLIPITOR and its metabolites are eliminated primarily in bile following hepatic and\/or extra-\nhepatic metabolism; however, the drug does not appear to undergo enterohepatic\nrecirculation. Mean plasma elimination half-life of LIPITOR in humans is approximately 14\nhours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours\ndue to the contribution of active metabolites. Less than 2% of a dose of LIPITOR is\nrecovered in urine following oral administration.\nSpecific Populations\nGeriatric\nPlasma concentrations of LIPITOR are higher (approximately 40% for Cmax and 30% for\nAUC) in healthy elderly subjects (age ≥65 years) than in young adults.\nPediatric\nApparent oral clearance of atorvastatin in pediatric subjects appeared similar to that of\nadults when scaled allometrically by body weight as the body weight was the only\nsignificant covariate in atorvastatin population PK model with data including pediatric\nHeFH patients (ages 10 years to 17 years of age, n=29) in an open-label, 8-week study.\nGender\nPlasma concentrations of LIPITOR in women differ from those in men (approximately\n20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant\ndifference in LDL-C reduction with LIPITOR between men and women.\nRenal Impairment\nRenal disease has no influence on the plasma concentrations or LDL-C reduction of\nLIPITOR \n[see \nUse in Specific Populations (8.6)\n]\n.\nWhile studies have not been conducted in patients with end-stage renal disease,\nhemodialysis is not expected to significantly enhance clearance of LIPITOR since the\ndrug is extensively bound to plasma proteins.\nHepatic Impairment\nIn patients with chronic alcoholic liver disease, plasma concentrations of LIPITOR are\nmarkedly increased. Cmax and AUC are each 4-fold greater in patients with Childs-Pugh\nA disease. Cmax and AUC are approximately 16-fold and 11-fold increased, respectively,\nin patients with Childs-Pugh B disease \n[see \nUse in Specific Populations (8.7)\n]\n.\nDrug Interactions\nAtorvastatin is a substrate of the hepatic transporters, OATP1B1 and OATP1B3\ntransporter. Metabolites of atorvastatin are substrates of OATP1B1. Atorvastatin is also\nidentified as a substrate of the efflux transporter BCRP, which may limit the intestinal\nabsorption and biliary clearance of atorvastatin.\nTable 5: Effect of Co-administered Drugs on the Pharmacokinetics of","conversation_history":[],"metadata":{"question_type":"simple","seed_document_id":91,"topic":"Atorvastatin Side Effects"}}
{"id":"76e4e628-e8be-4675-a04e-1208c39eb612","question":"What is the strength of ALBUTEROL SULFATE in the solution?","reference_answer":"The strength of ALBUTEROL SULFATE in the solution is 0.63 mg in 3 mL.","reference_context":"Document 215: ALBUTEROL SULFATE  \nalbuterol sulfate solution\nProduct Information\nProduct Type\nHUMAN PRESCRIPTION DRUG\nItem Code (Source)\nNDC:50742-392\nRoute of Administration\nRESPIRATORY (INHALATION)\nActive Ingredient\/Active Moiety\nIngredient Name\nBasis of Strength\nStrength\nALBUTEROL SULFATE\n (UNII: 021SEF3731) \n(ALBUTEROL - UNII:QF8SVZ843E)\nALBUTEROL\n0.63 mg  in 3 mL\nInactive Ingredients\nIngredient Name\nStrength\nSODIUM CHLORIDE\n (UNII: 451W47IQ8X)\n \nSULFURIC ACID\n (UNII: O40UQP6WCF)\n \nPackaging","conversation_history":[],"metadata":{"question_type":"simple","seed_document_id":215,"topic":"Albuterol Sulfate"}}
{"id":"3a0b5032-84e3-405d-a8c9-43d62cd79c3c","question":"What are the recommended precautions to be taken when discontinuing therapy with Lopressor, especially in patients with ischemic heart disease, and what is the suggested timeframe for gradually reducing the dosage?","reference_answer":"When discontinuing therapy with Lopressor, particularly in patients with ischemic heart disease, it is recommended to gradually reduce the dosage over a period of 1 to 2 weeks. Patients should be monitored, and if angina worsens or acute coronary ischemia develops, Lopressor should be promptly reinstated.","reference_context":"Document 181: been studied. If treatment is to be discontinued, reduce the dosage gradually over a\nperiod of 1 - 2 weeks \n[see \nWarnings and Precautions (\n5.1\n)\n].\n2.3 \n  \nMyocardial Infarction\nSee prescribing information of intravenous metoprolol for dosage instructions for\nintravenous therapy.\nIn patients who tolerate the full intravenous dose, initiate Lopressor tablets, 50 mg every\n6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for\n48 hours. In the case of intolerance, reduce dose to 25 mg and administer for 48 hours.\nTitrate, based on tolerability, to a maintenance dosage of 100 mg twice daily. Continue\ntherapy for at least 3 months. Although the efficacy of Lopressor beyond 3 months has\nnot been conclusively established, data from studies with other beta-blockers suggest\nthat treatment should be continued for 1 to 3 years.\n3 \n     \nDOSAGE FORMS AND STRENGTHS\nLOPRESSOR is supplied as:\n50 mg tablet – capsule shaped, biconvex, pink, scored (imprinted GEIGY on one side and\n51 twice on the scored side)\n100 mg tablet – capsule shaped, biconvex, light blue, scored (imprinted with GEIGY on\none side and 71 twice on the scored side)\n4 \n     \nCONTRAINDICATIONS\nLOPRESSOR is contraindicated in severe bradycardia, second- or third-degree heart\nblock, cardiogenic shock, systolic blood pressure <100, decompensated heart failure,\nsick sinus syndrome (unless a permanent pacemaker is in place), and in patients who\nare hypersensitive to any component of this product.\n5 \n     \nWARNINGS AND PRECAUTIONS\n5.1 \n  \nAbrupt Cessation of Therapy\nFollowing abrupt cessation of therapy with certain beta-blocking agents, exacerbations\nof angina pectoris and, in some cases, myocardial infarction have occurred. When\ndiscontinuing chronically administered LOPRESSOR, particularly in patients with ischemic\nheart disease, gradually reduce the dosage over a period of 1 to 2 weeks and monitor\nthe patient. If angina markedly worsens or acute coronary ischemia develops, promptly\nreinstate LOPRESSOR, and take measures appropriate for the management of unstable\nangina. Warn patients not to interrupt therapy without their physician’s advice. Because\ncoronary artery disease is common and may be unrecognized, avoid abruptly\ndiscontinuing LOPRESSOR in patients treated only for hypertension.\n5.2 \n  \nHeart Failure\nWorsening cardiac failure may occur during up-titration of LOPRESSOR. If such\nsymptoms occur, increase diuretics and restore clinical stability before advancing the","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":181,"topic":"Metoprolol Usage"}}
{"id":"2e22dd3f-eae2-446f-a07b-5410126788cd","question":"What adverse reactions have been reported during post approval use of Lopressor, including central nervous system, cardiovascular, hematologic, hypersensitive reactions, and laboratory findings?","reference_answer":"The adverse reactions identified during post approval use of Lopressor include reversible mental depression progressing to catatonia, an acute reversible syndrome characterized by disorientation, short-term memory loss, emotional lability, slightly clouded sensorium, decreased performance on neuropsychometrics, intensification of AV block, agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura, fever combined with aching and sore throat, laryngospasm, respiratory distress, increase in blood triglycerides, elevated transaminase, decrease in High Density Lipoprotein (HDL).","reference_context":"Document 184: Lopressor\nPlacebo\nHypotension (systolic BP < 90 mm\nHg)\n27.4%\n23.2%\nBradycardia (heart rate <\n40 beats\/min)\n15.9%\n6.7%\nSecond- or third-degree heart block\n4.7%\n4.7%\nFirst-degree heart block (P-R ≥\n0.26 sec)\n5.3%\n1.9%\nHeart failure\n27.5%\n29.6%\n6.2 \n  \nPost-Marketing Experience\nThe following adverse reactions have been identified during post approval use of\nLOPRESSOR. Because these reactions are reported voluntarily from a population of\nuncertain size, it is not always possible to reliably estimate their frequency or establish a\ncausal relationship to drug exposure.\nCentral Nervous System:\n Reversible mental depression progressing to catatonia; an\nacute reversible syndrome characterized by disorientation for time and place, short-\nterm memory loss, emotional lability, slightly clouded sensorium, and decreased\nperformance on neuropsychometrics.\nCardiovascular\n:\n Intensification of AV block \n[see Contraindications (\n4\n)].\n \nHematologic:\n Agranulocytosis, nonthrombocytopenic purpura and thrombocytopenic\npurpura.\nHypersensitive Reactions:\n Fever combined with aching and sore throat, laryngospasm\nand respiratory distress.\nLaboratory Findings:\nIncrease in blood triglycerides, elevated transaminase and decrease in High Density\nLipoprotein (HDL)\n7 \n     \nDRUG INTERACTIONS\n7.1 \n  \nCatecholamine Depleting Drugs\nCatecholamine depleting drugs (e.g., reserpine, monoamine oxidase (MAO) inhibitors)\nmay have an additive effect when given with beta-blocking agents. Observe patients\ntreated with LOPRESSOR plus a catecholamine depletor for evidence of hypotension or\nmarked bradycardia, which may produce vertigo, syncope, or postural hypotension.\n7.2 \n  \nEpinephrine\nWhile taking beta-blockers, patients with a history of severe anaphylactic reactions to a\nvariety of allergens may be more reactive to repeated challenge and may be\nunresponsive to the usual doses of epinephrine used to treat an allergic reaction.\n7.3 \n  \nCYP2D6 Inhibitors\nDrugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine,\n®","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":184,"topic":"Metoprolol Usage"}}
{"id":"9841987e-789f-4d82-a021-cebe8fda092e","question":"When prescribing medication to geriatric patients, what is the recommended approach regarding the dosing range?","reference_answer":"For geriatric patients, it is recommended to start dosing at the low end of the dose range.","reference_context":"Document 148: USE IN SPECIFIC POPULATIONS\n•\n•\nSee 17 for FDA-approved patient labeling.\nRevised: 1\/2019\nFULL PRESCRIBING INFORMATION: CONTENTS\n*\n1 INDICATIONS AND USAGE\n1.1 Hypertension\n1.2 Coronary Artery Disease (CAD)\n2 DOSAGE AND ADMINISTRATION\n2.1 Adults\n2.2 Children\n3 DOSAGE FORMS AND STRENGTHS\n4 CONTRAINDICATIONS\n5 WARNINGS AND PRECAUTIONS\n5.1 Hypotension\n5.2 Increased Angina or Myocardial Infarction\n5.3 Patients with Hepatic Failure\n6 ADVERSE REACTIONS\n6.1 Clinical Trials Experience\n6.2 Postmarketing Experience\n7 DRUG INTERACTIONS\n7.1 Impact of Other Drugs on Amlodipine\n7.2 Impact of Amlodipine on Other Drugs\n8 USE IN SPECIFIC POPULATIONS\n8.1 Pregnancy\n8.2 Lactation\n8.4 Pediatric Use\n8.5 Geriatric Use\n10 OVERDOSAGE\n11 DESCRIPTION\n12 CLINICAL PHARMACOLOGY\n12.1 Mechanism of Action\n12.2 Pharmacodynamics\n12.3 Pharmacokinetics\n12.4 Pediatric Patients\n13 NONCLINICAL TOXICOLOGY\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\n14 CLINICAL STUDIES\n14.1 Effects in Hypertension\n14.2 Effects in Chronic Stable Angina\n14.3 Effects in Vasospastic Angina\n14.4 Effects in Documented Coronary Artery Disease\n14.5 Studies in Patients with Heart Failure\nPediatric: Effect on patients less than 6 years old is not known. (\n8.4\n)\nGeriatric: Start dosing at the low end of the dose range. (\n8.5\n)","conversation_history":[],"metadata":{"question_type":"distracting element","seed_document_id":148,"distracting_context":"Route of Administration\nORAL\nActive Ingredient\/Active Moiety\nIngredient Name\nBasis of Strength\nStrength\nIBUPROFEN\n (UNII: WK2XYI10QM) \n(IBUPROFEN - UNII:WK2XYI10QM)\nIBUPROFEN\n200 mg\nInactive Ingredients\nIngredient Name\nStrength\nMICROCRYSTALLINE CELLULOSE\n (UNII: OP1R32D61U)\n \nCROSCARMELLOSE SODIUM\n (UNII: M28OL1HH48)\n \nFERRIC OXIDE RED\n (UNII: 1K09F3G675)\n \nMETHYLPARABEN\n (UNII: A2I8C7HI9T)\n \nPOVIDONE, UNSPECIFIED\n (UNII: FZ989GH94E)\n \nPROPYLPARABEN\n (UNII: Z8IX2SC1OH)\n \nSHELLAC\n (UNII: 46N107B71O)\n \nSILICON DIOXIDE\n (UNII: ETJ7Z6XBU4)\n \nSODIUM BENZOATE\n (UNII: OJ245FE5EU)\n \nSODIUM LAURYL SULFATE\n (UNII: 368GB5141J)\n \nSTARCH, CORN\n (UNII: O8232NY3SJ)\n \nSTEARIC ACID\n (UNII: 4ELV7Z65AP)\n \nSUCROSE\n (UNII: C151H8M554)\n \nTITANIUM DIOXIDE\n (UNII: 15FIX9V2JP)\n \nWHITE WAX\n (UNII: 7G1J5DA97F)\n \nDIACETYLATED MONOGLYCERIDES\n (UNII: 5Z17386USF)\n \nProduct Characteristics\nColor\nbrown (pinkish brown)\nScore\nno score\nShape\nROUND\nSize\n11mm\nFlavor\nImprint Code\nAdvil\nContains\n    \nPackaging\n#\nItem Code\nPackage Description\nMarketing Start\nDate\nMarketing End\nDate\n1\nNDC:0573-1711-\n14\n1 \nin 1 CARTON\n05\/18\/1984\n1\n225 \nin 1 BOTTLE; Type 0: Not a Combination\nProduct\nMarketing Information\nMarketing\nCategory\nApplication Number or Monograph\nCitation\nMarketing Start\nDate\nMarketing End\nDate\nNDA\nNDA018989\n05\/18\/1984","topic":"Amlodipine Side Effects"}}
{"id":"73e18ef5-254e-44e7-9171-26ca90d40210","question":"Can you provide the list of inactive ingredients in Lipitor 40mg tablets for patients with allergies to Hypromellose?","reference_answer":"The inactive ingredients in Lipitor 40mg tablets are Hypromellose, Polyethylene Glycol, Talc, Titanium Dioxide, and Polysorbate 80.","reference_context":"Document 114: CALCIUM CARBONATE\n (UNII: H0G9379FGK)\n \nCANDELILLA WAX\n (UNII: WL0328HX19)\n \nCROSCARMELLOSE SODIUM\n (UNII: M28OL1HH48)\n \nHYDROXYPROPYL CELLULOSE (1600000 WAMW)\n (UNII: RFW2ET671P)\n \nLACTOSE MONOHYDRATE\n (UNII: EWQ57Q8I5X)\n \nMAGNESIUM STEARATE\n (UNII: 70097M6I30)\n \nMICROCRYSTALLINE CELLULOSE\n (UNII: OP1R32D61U)\n \nHYPROMELLOSE, UNSPECIFIED\n (UNII: 3NXW29V3WO)\n \nPOLYETHYLENE GLYCOL, UNSPECIFIED\n (UNII: 3WJQ0SDW1A)\n \nTALC\n (UNII: 7SEV7J4R1U)\n \nTITANIUM DIOXIDE\n (UNII: 15FIX9V2JP)\n \nPOLYSORBATE 80\n (UNII: 6OZP39ZG8H)\n \nProduct Characteristics\nColor\nWHITE\nScore\nno score\nShape\nOVAL (elliptical)\nSize\n15mm\nFlavor\nImprint Code\nPD;157;40\nContains\n    \nPackaging\n#\nItem Code\nPackage Description\nMarketing Start\nDate\nMarketing End\nDate\n1\nNDC:0071-0157-\n23\n90 \nin 1 BOTTLE; Type 0: Not a Combination\nProduct\n12\/17\/1996\n03\/31\/2026\n2\nNDC:0071-0157-\n40\n100 \nin 1 CARTON\n12\/17\/1996\n09\/30\/2023\n2\n1 \nin 1 BLISTER PACK; Type 0: Not a Combination\nProduct\nMarketing Information\nMarketing\nCategory\nApplication Number or Monograph\nCitation\nMarketing Start\nDate\nMarketing End\nDate\nNDA\nNDA020702\n12\/17\/1996\n03\/31\/2026\nLIPITOR  \natorvastatin calcium tablet, film coated\nProduct Information\nProduct Type\nHUMAN PRESCRIPTION DRUG\nItem Code (Source)\nNDC:0071-0158\nRoute of Administration\nORAL\nActive Ingredient\/Active Moiety\nIngredient Name\nBasis of\nStrength\n\nDocument 113: HYPROMELLOSE, UNSPECIFIED\n (UNII: 3NXW29V3WO)\n \nPOLYETHYLENE GLYCOL, UNSPECIFIED\n (UNII: 3WJQ0SDW1A)\n \nTALC\n (UNII: 7SEV7J4R1U)\n \nTITANIUM DIOXIDE\n (UNII: 15FIX9V2JP)\n \nPOLYSORBATE 80\n (UNII: 6OZP39ZG8H)\n \nProduct Characteristics\nColor\nWHITE\nScore\nno score\nShape\nOVAL (elliptical)\nSize\n12mm\nFlavor\nImprint Code\nPD;156;20\nContains\n    \nPackaging\n#\nItem Code\nPackage Description\nMarketing Start\nDate\nMarketing End\nDate\n1\nNDC:0071-0156-\n23\n90 \nin 1 BOTTLE; Type 0: Not a Combination\nProduct\n12\/17\/1996\n09\/30\/2025\n2\nNDC:0071-0156-\n40\n100 \nin 1 CARTON\n12\/17\/1996\n11\/30\/2023\n2\n1 \nin 1 BLISTER PACK; Type 0: Not a Combination\nProduct\nMarketing Information\nMarketing\nCategory\nApplication Number or Monograph\nCitation\nMarketing Start\nDate\nMarketing End\nDate\nNDA\nNDA020702\n12\/17\/1996\n09\/30\/2025\nLIPITOR  \natorvastatin calcium tablet, film coated\nProduct Information\nProduct Type\nHUMAN PRESCRIPTION DRUG\nItem Code (Source)\nNDC:0071-0157\nRoute of Administration\nORAL\nActive Ingredient\/Active Moiety\nIngredient Name\nBasis of\nStrength\nStrength\nATORVASTATIN CALCIUM TRIHYDRATE\n (UNII: 48A5M73Z4Q) \n(ATORVASTATIN -\nUNII:A0JWA85V8F)\nATORVASTATIN\n40 mg\nInactive Ingredients\nIngredient Name\nStrength","conversation_history":[],"metadata":{"question_type":"distracting element","seed_document_id":114,"distracting_context":"PRINCIPAL DISPLAY PANEL - 10 mg Tablet Bottle Label\nNDC 0069-1540-68\nPfizer\nNorvasc \n \n(amlodipine besylate)\ntablets\n10 mg*\n90 Tablets\nRx only\n®","topic":"Pharmaceuticals"}}
{"id":"7cd4bf5b-e8b5-412d-9015-7fc4967b63d2","question":"Can you please confirm the active ingredient and its strength in the Albuterol sulfate solution you are checking the packaging information for?","reference_answer":"The active ingredient in the ALBUTEROL SULFATE solution is ALBUTEROL SULFATE, with a strength of 1.25 mg in 3 mL.","reference_context":"Document 216: #\nItem Code\nPackage Description\nMarketing Start\nDate\nMarketing End\nDate\n1\nNDC:50742-392-\n25\n5 \nin 1 CARTON\n11\/01\/2024\n1\nNDC:50742-392-\n05\n5 \nin 1 POUCH\n1\n3 mL in 1 VIAL; Type 0: Not a Combination\nProduct\nMarketing Information\nMarketing\nCategory\nApplication Number or Monograph\nCitation\nMarketing Start\nDate\nMarketing End\nDate\nANDA\nANDA215571\n11\/01\/2024\nALBUTEROL SULFATE  \nalbuterol sulfate solution\nProduct Information\nProduct Type\nHUMAN PRESCRIPTION DRUG\nItem Code (Source)\nNDC:50742-393\nRoute of Administration\nRESPIRATORY (INHALATION)\nActive Ingredient\/Active Moiety\nIngredient Name\nBasis of Strength\nStrength\nALBUTEROL SULFATE\n (UNII: 021SEF3731) \n(ALBUTEROL - UNII:QF8SVZ843E)\nALBUTEROL\n1.25 mg  in 3 mL\nInactive Ingredients\nIngredient Name\nStrength\nSODIUM CHLORIDE\n (UNII: 451W47IQ8X)\n \nSULFURIC ACID\n (UNII: O40UQP6WCF)\n \nPackaging\n#\nItem Code\nPackage Description\nMarketing Start\nDate\nMarketing End\nDate\n1\nNDC:50742-393-\n25\n5 \nin 1 CARTON\n11\/01\/2024\n1\nNDC:50742-393-\n05\n5 \nin 1 POUCH\n1\n3 mL in 1 VIAL; Type 0: Not a Combination\nProduct\nMarketing Information\nMarketing\nCategory\nApplication Number or Monograph\nCitation\nMarketing Start\nDate\nMarketing End\nDate","conversation_history":[],"metadata":{"question_type":"situational","seed_document_id":216,"situational_context":"A pharmacist is checking the packaging information for Albuterol sulfate solution.","topic":"Albuterol Sulfate"}}
{"id":"b2c26aad-f9f9-4ee5-b69c-4c8ef13097ba","question":"What are some of the risk factors for developing myopathy while taking Lipitor that I should be aware of?","reference_answer":"Risk factors for myopathy associated with LIPITOR include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher LIPITOR dosage.","reference_context":"Document 78: Select Azole Antifungals or Macrolide Antibiotics\n•\nFor additional recommendations regarding concomitant use of LIPITOR with other anti-\nviral medications, azole antifungals or macrolide antibiotics, \nsee \nDrug Interactions (7.1)\n.\n3 DOSAGE FORMS AND STRENGTHS\nLIPITOR tablets:\n•\n•\n•\n•\n4 CONTRAINDICATIONS\n•\n•\n5 WARNINGS AND PRECAUTIONS\n5.1 Myopathy and Rhabdomyolysis\nLIPITOR may cause myopathy (muscle pain, tenderness, or weakness associated with\nelevated creatine kinase [CK]) and rhabdomyolysis. Acute kidney injury secondary to\nmyoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients\ntreated with statins, including LIPITOR.\nRisk Factors for Myopathy\nRisk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism,\nrenal impairment, concomitant use with certain other drugs (including other lipid-\nlowering therapies), and higher LIPITOR dosage \n[see \nDrug Interactions (7.1)\n and \nUse in\nSpecific Populations (8.5\n, \n8.6)\n]\n.\nSteps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis\nLIPITOR exposure may be increased by drug interactions due to inhibition of\ncytochrome P450 enzyme 3A4 (CYP3A4) and\/or transporters (e.g., breast cancer\nresistant protein [BCRP], organic anion-transporting polypeptide [OATP1B1\/OATP1B3]\nIn patients taking clarithromycin or itraconazole, do not exceed LIPITOR 20 mg\nonce daily.\n10 mg of atorvastatin: white elliptical, film-coated tablets with “PD 155” on one side\nand “10” on the other\n20 mg of atorvastatin: white elliptical, film-coated tablets with “PD 156” on one side\nand “20” on the other\n40 mg of atorvastatin: white elliptical, film-coated tablets with “PD 157” on one side\nand “40” on the other\n80 mg of atorvastatin: white elliptical, film-coated tablets with “PD 158” on one side\nand “80” on the other\nAcute liver failure or decompensated cirrhosis \n[see \nWarnings and Precautions (5.3)\n]\nHypersensitivity to atorvastatin or any excipients in LIPITOR. Hypersensitivity\nreactions, including anaphylaxis, angioneurotic edema, erythema multiforme,\nStevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported\n[see \nAdverse Reactions (6.2)\n]\n.","conversation_history":[],"metadata":{"question_type":"situational","seed_document_id":78,"situational_context":"A person is reading about the medication Lipitor and its potential interactions and risks.","topic":"Atorvastatin Side Effects"}}
{"id":"92d517b2-54d4-44ce-a923-08c44e3c6ed3","question":"What instructions should patients be given when taking Atovaquone and Proguanil Hydrochloride tablets and what are the risks associated with falciparum malaria in pregnant women?","reference_answer":"Patients should be instructed to take a repeat dose if vomiting occurs within 1 hour after dosing, and to consult a healthcare professional if prophylaxis is prematurely discontinued. Falciparum malaria carries a higher risk of death and serious complications in pregnant women than in the general population.","reference_context":"Document 361: Product: \n50090-2980\nNDC: \n50090-2980-0 \n7 TABLET, FILM COATED in a BOTTLE\nNDC: \n50090-2980-1 \n12 TABLET, FILM COATED in a BOTTLE\nNDC: \n50090-2980-2 \n14 TABLET, FILM COATED in a BOTTLE\nNDC: \n50090-2980-3 \n16 TABLET, FILM COATED in a BOTTLE\nNDC: \n50090-2980-4 \n24 TABLET, FILM COATED in a BOTTLE\nNDC: \n50090-2980-5 \n5 TABLET, FILM COATED in a BOTTLE\nNDC: \n50090-2980-6 \n10 TABLET, FILM COATED in a BOTTLE\nNDC: \n50090-2980-7 \n100 TABLET, FILM COATED in a BOTTLE\nNDC: \n50090-2980-8 \n20 TABLET, FILM COATED in a BOTTLE\nNDC: \n50090-2980-9 \n30 TABLET, FILM COATED in a BOTTLE\n17 PATIENT COUNSELING INFORMATION\nPatients should be instructed:\n•\n•\n•\n•\n•\n•\n•\n•\nManufactured for:\nPrasco Laboratories\nto take Atovaquone and Proguanil Hydrochloride tablets at the same time each day\nwith food or a milky drink.\nto take a repeat dose of Atovaquone and Proguanil Hydrochloride tablets if vomiting\noccurs within 1 hour after dosing.\nto take a dose as soon as possible if a dose is missed, then return to their normal\ndosing schedule. However, if a dose is skipped, the patient should not double the\nnext dose.\nthat rare serious adverse events such as hepatitis, severe skin reactions,\nneurological events, and hematological events have been reported when\natovaquone and proguanil hydrochloride was used for the prophylaxis or treatment\nof malaria.\nto consult a healthcare professional regarding alternative forms of prophylaxis if\nprophylaxis with Atovaquone and Proguanil Hydrochloride tablets is prematurely\ndiscontinued for any reason.\nthat protective clothing, insect repellents, and bed nets are important components\nof malaria prophylaxis.\nthat no chemoprophylactic regimen is 100% effective; therefore, patients should\nseek medical attention for any febrile illness that occurs during or after return from\na malaria-endemic area and inform their healthcare professional that they may have\nbeen exposed to malaria.\nthat falciparum malaria carries a higher risk of death and serious complications in\npregnant women than in the general population. Pregnant women anticipating travel\nto malarious areas should discuss the risks and benefits of such travel with their\nphysicians.","conversation_history":[],"metadata":{"question_type":"double","original_questions":[{"question":"What instructions should patients be given when taking Atovaquone and Proguanil Hydrochloride tablets?","answer":"Patients should be instructed to take a repeat dose if vomiting occurs within 1 hour after dosing, and to consult a healthcare professional if prophylaxis is prematurely discontinued."},{"question":"What are the risks associated with falciparum malaria in pregnant women?","answer":"Falciparum malaria carries a higher risk of death and serious complications in pregnant women than in the general population."}],"seed_document_id":361,"topic":"Atovaquone and Proguanil"}}
{"id":"c940d678-3141-4420-b01d-6ab2179e11d3","question":"What should be done?","reference_answer":"Patients prescribed ZOLOFT oral solution should be informed not to take disulfiram when taking ZOLOFT oral solution, as concomitant use is contraindicated due to the alcohol content of the oral solution.","reference_context":"Document 320: Suicidal Thoughts and Behaviors\nAdvise patients and caregivers to look for the emergence of suicidality, especially early\nduring treatment and when the dosage is adjusted up or down, and instruct them to\nreport such symptoms to the healthcare provider \n[See \nBoxed Warning\n and \nWarnings\nand Precautions (5.1)\n]\n.\nImportant Administration Instructions for Oral Solution\nFor patients prescribed ZOLOFT oral solution, inform them that:\n•\n•\n•\n•\nDisulfiram Contraindication for ZOLOFT Oral Solution\nInform patients not to take disulfiram when taking ZOLOFT oral solution. Concomitant\nuse is contraindicated due the alcohol content of the oral solution \n[See \nContraindication\n(4)\n]\n.\nSerotonin Syndrome\nCaution patients about the risk of serotonin syndrome, particularly with the concomitant\nuse of ZOLOFT with other serotonergic drugs including triptans, tricyclic\nantidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St.\nJohn’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs,\nboth those intended to treat psychiatric disorders and also others, such as linezolid).\nPatients should contact their health care provider or report to the emergency room if\nthey experience signs or symptoms of serotonin syndrome \n[See \nWarnings and\nPrecautions (5.2)\n, \nDrug Interactions (7.1)\n]\n.\nIncreased Risk of Bleeding\nInform patients about the concomitant use of ZOLOFT with aspirin, NSAIDs, other\nantiplatelet drugs, warfarin, or other anticoagulants because the combined use has been\nassociated with an increased risk of bleeding. Advise patients to inform their health care\nproviders if they are taking or planning to take any prescription or over-the-counter\nmedications that increase the risk of bleeding \n[See \nWarnings and Precautions (5.3)\n]\n.\nActivation of Mania\/Hypomania\nAdvise patients and their caregivers to observe for signs of activation of\nmania\/hypomania and instruct them to report such symptoms to the healthcare\nprovider \n[See \nWarnings and Precautions (5.4)\n]\n.\nDiscontinuation Syndrome\nAdvise patients not to abruptly discontinue ZOLOFT and to discuss any tapering\nregimen with their healthcare provider. Adverse reactions can occur when ZOLOFT is\nZOLOFT oral solution must be diluted before use. Do not mix in advance.\nUse the dropper provided to remove the required amount of ZOLOFT oral solution\nand mix with 4 ounces (1\/2 cup) of water, ginger ale, lemon\/lime soda, lemonade or\norange juice ONLY. Do not mix ZOLOFT oral solution with anything other than the\nliquids listed.\nTake the dose immediately after mixing. At times, a slight haze may appear after\nmixing; this is normal.\nThe dropper dispenser contains dry natural rubber, a consideration for patients\nwith latex sensitivity.","conversation_history":[{"role":"user","content":"Patients prescribed ZOLOFT oral solution need important instructions."},{"role":"assistant","content":"How can I help you with that?"}],"metadata":{"question_type":"conversational","seed_document_id":320,"topic":"Sertraline Use in Elderly Patients"}}
